LUMOS PHARMA, INC. (LUMO) Debt-to-equity % [USD] 2018 - 2024

Historical data

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Lumos Pharma, Inc. quarterly Debt-to-equity history and growth rate from 2018 to 2024.
Lumos Pharma, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 39.5 %, a 117% increase year-over-year.

Debt-to-equity, Quarterly (% [USD])

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q1 2024	39.5	+21.3	+117%	Mar 31, 2024
Q4 2023	31.1	+14.8	+90%	Dec 31, 2023
Q3 2023	25.6	+11.2	+77.4%	Sep 30, 2023
Q2 2023	21.5	+8	+59.1%	Jun 30, 2023
Q1 2023	18.2	+5.05	+38.4%	Mar 31, 2023
Q4 2022	16.4	+4.2	+34.5%	Dec 31, 2022
Q3 2022	14.4	+2.76	+23.7%	Sep 30, 2022
Q2 2022	13.5	+1.33	+10.9%	Jun 30, 2022
Q1 2022	13.2	-7.88	-37.4%	Mar 31, 2022
Q4 2021	12.2	-18.9	-60.8%	Dec 31, 2021
Q3 2021	11.7	-34.2	-74.6%	Sep 30, 2021
Q2 2021	12.2	-101	-89.3%	Jun 30, 2021
Q1 2021	21.1	+243		Mar 31, 2021
Q4 2020	31.1	+61.4		Dec 31, 2020
Q3 2020	45.9	+84.9		Sep 30, 2020
Q2 2020	114	+395		Jun 30, 2020
Q1 2020	-222	-274	-528%	Mar 31, 2020
Q4 2019	-30.2	-54.8	-223%	Dec 31, 2019
Q3 2019	-39	-57	-317%	Sep 30, 2019
Q2 2019	-281	-303	-1403%	Jun 30, 2019
Q1 2019	52	+27.3	+111%	Mar 31, 2019
Q4 2018	24.6			Dec 31, 2018
Q3 2018	18			Sep 30, 2018
Q2 2018	21.6			Jun 30, 2018
Q1 2018	24.7			Mar 31, 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.